​

Viridian Therapeutics (VRDN) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

VRDN Stock Forecast

Viridian Therapeutics stock forecast is as follows: an average price target of $22.75 (represents a 19.55% upside from VRDN’s last price of $19.03) and a rating consensus of 'Buy', based on 11 wall street analysts offering a 1-year stock forecast.

VRDN Price Target

The average price target for Viridian Therapeutics (VRDN) is $22.75 based on 1-year price targets from 11 Wall Street analysts in the past 3 months, with a price target range of $28.00 to $19.00. This represents a potential 19.55% upside from VRDN's last price of $19.03.

VRDN Analyst Ratings

Buy

According to 11 Wall Street analysts, Viridian Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for VRDN stock is 0 'Strong Buy' (0.00%), 10 'Buy' (90.91%), 1 'Hold' (9.09%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Viridian Therapeutics Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 12, 2024Alex ThompsonStifel Nicolaus$20.50$11.4179.67%7.72%
Sep 13, 2024Gregory RenzaRBC Capital$22.00$10.35112.56%15.61%
Sep 11, 2024Serge BelangerNeedham$19.00$9.5199.79%-0.16%
Sep 11, 2024Kalpit PatelB.Riley Financial$22.00$19.2414.35%15.61%
Sep 10, 2024Alex ThompsonStifel Nicolaus$20.00$8.68130.41%5.10%
Sep 10, 2024Julian HarrisonBTIG$28.00$8.64224.07%47.14%
Aug 14, 2024Richard LawGoldman Sachs$25.00$14.1876.30%31.37%
Jun 11, 2024Gregory RenzaRBC Capital$17.50$6.48170.06%-8.04%
Jun 11, 2024Julian HarrisonBTIG$23.00$6.48254.94%20.86%
Jun 10, 2024Andy ChenWolfe Research$14.50$6.11137.32%-23.80%
Jun 06, 2024Richard LawGoldman Sachs$11.50$6.1786.39%-39.57%
May 09, 2024Leland GershellOppenheimer$15.50$7.45108.05%-18.55%
May 09, 2024Douglas TsaoH.C. Wainwright$13.50$7.4581.21%-29.06%
May 09, 2024Kalpit PatelB.Riley Financial$20.00$14.9034.23%5.10%
Jan 09, 2023Leerink Partners$45.00$27.4663.87%136.47%
Dec 19, 2022Needham$45.00$27.8861.41%136.47%
Dec 16, 2022Credit Suisse$25.50$13.8584.12%34.00%
Dec 01, 2022H.C. Wainwright$35.00$25.2738.50%83.92%
Nov 15, 2022JMP Securities$23.00$10.82112.57%20.86%

The latest Viridian Therapeutics stock forecast, released on Nov 12, 2024 by Alex Thompson from Stifel Nicolaus, set a price target of $20.50, which represents a 79.67% increase from the stock price at the time of the forecast ($11.41), and a 7.72% increase from VRDN last price ($19.03).

Viridian Therapeutics Price Target by Period

1M3M12M
# Anlaysts-114
Avg Price Target-$20.50$19.43
Last Closing Price$19.03$19.03$19.03
Upside/Downside-100.00%7.72%2.10%

In the current month, the average price target of Viridian Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Viridian Therapeutics's last price of $19.03. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Oct 28, 2024NeedhamBuyBuyHold
Sep 13, 2024RBC CapitalOutperformOutperformHold
Sep 11, 2024NeedhamBuyBuyHold
Sep 11, 2024H.C. WainwrightBuyBuyHold
Sep 10, 2024RBC CapitalUnderperformUnderperformHold
Sep 10, 2024WedbushBuyBuyHold
Sep 10, 2024BTIGBuyBuyHold
Aug 15, 2024WedbushBuyBuyHold
Aug 15, 2024OppenheimerUnderperformUnderperformHold
Aug 14, 2024Goldman SachsBuyBuyHold
Jul 16, 2024NeedhamUnderperformUnderperformHold
Jul 16, 2024OppenheimerBuyBuyHold
Jun 11, 2024Goldman SachsBuyBuyHold
Jun 11, 2024RBC CapitalOutperformOutperformHold
Jun 11, 2024BTIGBuyBuyHold
Jun 10, 2024Wolfe ResearchOutperformInitialise
Jun 06, 2024OppenheimerBuyBuyHold
Jun 06, 2024NeedhamUnderperformUnderperformHold
Jun 06, 2024Goldman SachsBuyInitialise
May 09, 2024OppenheimerOutperformOutperformHold
May 09, 2024H.C. WainwrightBuyBuyHold
May 09, 2024B. RileyBuyNeutralDowngrade
Mar 20, 2024NeedhamUnderperformUnderperformHold
Mar 20, 2024WedbushBuyBuyHold
Feb 28, 2024RBC CapitalUnderperformUnderperformHold
Feb 28, 2024WedbushBuyBuyHold
Aug 10, 2023NeedhamBuyBuyHold
Jan 09, 2023SVB LeerinkOutperformOutperformHold
Dec 19, 2022NeedhamBuyInitialise
Dec 16, 2022Credit SuisseOutperformInitialise
Nov 15, 2022JMP SecuritiesMarket OutperformMarket OutperformHold
Jun 23, 2022B. RileyBuyInitialise

Viridian Therapeutics's last stock rating was published by Needham on Oct 28, 2024. The company gave VRDN a "Buy" rating, the same as its previous rate.

Viridian Therapeutics Financial Forecast

Viridian Therapeutics Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19
Revenue-------------$72.00K$72.00K$98.00K$105.00K$1.20M$256.00K$216.00K$214.00K$208.00K$1.45M$54.00K-$168.00K$828.00K$880.00K$695.00K$2.51M
Avg Forecast$25.81M$48.72K$52.30K$56.16K$87.50K$70.00K$60.00K$60.00K$50.69K$84.92K$78.15K$88.10K$154.18K$145.25K$254.00K$116.78K$457.60K$303.33K$270.33K$253.50K$342.80K$454.20K$2.39M$80.00K$206.00K$645.25K$582.50K$728.50K$1.25M$372.00K
High Forecast$34.41M$64.96K$69.74K$74.87K$116.67K$93.33K$80.00K$80.00K$56.32K$113.22K$78.23K$88.15K$171.31K$147.38K$338.67K$155.70K$610.13K$303.33K$270.33K$253.50K$342.80K$454.20K$2.87M$80.00K$206.00K$645.25K$582.50K$728.50K$1.25M$372.00K
Low Forecast$17.21M$32.48K$34.87K$37.44K$58.33K$46.67K$40.00K$40.00K$39.43K$56.61K$78.08K$88.05K$119.92K$143.13K$169.33K$77.85K$305.07K$303.33K$270.33K$253.50K$342.80K$454.20K$1.91M$80.00K$206.00K$645.25K$582.50K$728.50K$1.25M$372.00K
# Analysts2222111484336333445566129999555
Surprise %-------------0.50%0.28%0.84%0.23%3.94%0.95%0.85%0.62%0.46%0.61%0.68%-0.26%1.42%1.21%0.55%6.76%

Viridian Therapeutics's average Quarter revenue forecast for Dec 23 based on 6 analysts is $154.18K, with a low forecast of $119.92K, and a high forecast of $171.31K. VRDN's average Quarter revenue forecast represents a 114.14% increase compared to the company's last Quarter revenue of $72.00K (Sep 23).

Viridian Therapeutics EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19
# Analysts2222111484336333445566129999555
EBITDA-------------$-51.22M$-59.27M$-67.99M$-45.62M$-28.68M$-29.28M$-25.85M$-28.91M$-14.01M$-18.43M$-90.51M$-5.34M$-6.28M$-7.83M$-9.88M$-10.96M$-8.60M
Avg Forecast$-25.81M$-48.72K$-52.30K$-56.16K$-87.50K$-70.00K$-60.00K$-60.00K$-50.69K$-84.92K$-78.15K$-88.10K$-154.18K$-145.25K$-254.00K$-116.78K$-457.60K$-303.33K$-270.33K$-253.50K$-342.80K$-454.20K$-30.33M$-80.00K$-206.00K$-645.25K$-582.50K$-728.50K$-1.25M$-372.00K
High Forecast$-17.21M$-32.48K$-34.87K$-37.44K$-58.33K$-46.67K$-40.00K$-40.00K$-39.43K$-56.61K$-78.08K$-88.05K$-119.92K$-143.13K$-169.33K$-77.85K$-305.07K$-303.33K$-270.33K$-253.50K$-342.80K$-454.20K$-24.27M$-80.00K$-206.00K$-645.25K$-582.50K$-728.50K$-1.25M$-372.00K
Low Forecast$-34.41M$-64.96K$-69.74K$-74.87K$-116.67K$-93.33K$-80.00K$-80.00K$-56.32K$-113.22K$-78.23K$-88.15K$-171.31K$-147.38K$-338.67K$-155.70K$-610.13K$-303.33K$-270.33K$-253.50K$-342.80K$-454.20K$-36.40M$-80.00K$-206.00K$-645.25K$-582.50K$-728.50K$-1.25M$-372.00K
Surprise %-------------352.66%233.37%582.18%99.69%94.55%108.31%101.97%84.34%30.85%0.61%1131.40%25.94%9.73%13.45%13.56%8.74%23.11%

undefined analysts predict VRDN's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Viridian Therapeutics's previous annual EBITDA (undefined) of $NaN.

Viridian Therapeutics Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19
# Analysts2222111484336333445566129999555
Net Income-------------$-47.66M$-55.06M$-68.05M$-42.50M$-28.02M$-29.42M$-25.50M$-28.95M$-14.04M$-18.46M$-90.74M$-5.49M$-6.43M$-8.04M$-10.12M$-11.23M$-8.90M
Avg Forecast$-63.10M$-77.05M$-80.37M$-77.71M$-70.81M$-67.46M$-68.28M$-66.03M$-68.77M$-70.22M$-57.84M$-72.34M$-64.95M$-82.72M$-83.73M$-67.12M$-48.38M$-62.76M$-57.29M$-62.26M$-53.36M$-80.03M$-30.39M$-108.34M$-126.91M$-158.04M$-183.90M$-241.37M$-283.51M$-356.79M
High Forecast$-35.76M$-43.66M$-45.54M$-44.04M$-40.12M$-38.23M$-38.69M$-63.44M$-57.63M$-39.79M$-32.77M$-40.99M$-52.92M$-46.87M$-47.45M$-38.04M$-27.41M$-62.76M$-57.29M$-62.26M$-53.36M$-80.03M$-24.31M$-108.34M$-126.91M$-158.04M$-183.90M$-241.37M$-283.51M$-356.79M
Low Forecast$-90.44M$-110.43M$-115.19M$-111.39M$-101.49M$-96.70M$-97.87M$-67.97M$-77.28M$-100.65M$-82.90M$-103.68M$-83.59M$-118.56M$-120.02M$-96.21M$-69.34M$-62.76M$-57.29M$-62.26M$-53.36M$-80.03M$-36.46M$-108.34M$-126.91M$-158.04M$-183.90M$-241.37M$-283.51M$-356.79M
Surprise %-------------0.58%0.66%1.01%0.88%0.45%0.51%0.41%0.54%0.18%0.61%0.84%0.04%0.04%0.04%0.04%0.04%0.02%

Viridian Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. VRDN's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Viridian Therapeutics SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19
# Analysts2222111484336333445566129999555
SG&A-------------$20.91M$19.26M$21.83M$9.85M$8.86M$8.11M$8.36M$6.90M$6.22M$6.16M$5.54M$2.30M$2.71M$2.72M$2.53M$2.90M$2.86M
Avg Forecast$1.79B$3.37M$3.62M$3.89M$6.06M$4.85M$4.16M$4.16M$3.51M$5.88M$5.41M$6.10M$10.68M$10.06M$17.59M$8.09M$31.70M$21.01M$18.73M$17.56M$23.75M$31.46M$165.45M$5.54M$14.27M$44.70M$40.35M$50.46M$86.83M$25.77M
High Forecast$2.38B$4.50M$4.83M$5.19M$8.08M$6.47M$5.54M$5.54M$3.90M$7.84M$5.42M$6.11M$11.87M$10.21M$23.46M$10.79M$42.26M$21.01M$18.73M$17.56M$23.75M$31.46M$198.54M$5.54M$14.27M$44.70M$40.35M$50.46M$86.83M$25.77M
Low Forecast$1.19B$2.25M$2.42M$2.59M$4.04M$3.23M$2.77M$2.77M$2.73M$3.92M$5.41M$6.10M$8.31M$9.91M$11.73M$5.39M$21.13M$21.01M$18.73M$17.56M$23.75M$31.46M$132.36M$5.54M$14.27M$44.70M$40.35M$50.46M$86.83M$25.77M
Surprise %-------------2.08%1.09%2.70%0.31%0.42%0.43%0.48%0.29%0.20%0.04%1.00%0.16%0.06%0.07%0.05%0.03%0.11%

Viridian Therapeutics's average Quarter SG&A projection for Dec 23 is $10.68M, based on 6 Wall Street analysts, with a range of $8.31M to $11.87M. The forecast indicates a -48.93% fall compared to VRDN last annual SG&A of $20.91M (Sep 23).

Viridian Therapeutics EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19
# Analysts2222111484336333445566129999555
EPS-------------$-1.09$-0.00$-1.61$-1.05$-0.83$-1.06$-0.98$-2.59$-1.25$-2.91$-23.07$-1.50$-1.80$-2.70$-4.65$-5.40$-4.35
Avg Forecast$-0.95$-1.16$-1.21$-1.17$-1.07$-1.02$-1.03$-0.99$-1.04$-1.06$-0.87$-1.09$-0.98$-1.25$-1.26$-1.01$-0.73$-0.98$-0.90$-0.97$-0.84$-1.25$-0.76$-1.70$-1.99$-2.48$-2.88$-3.78$-4.44$-5.59
High Forecast$-0.54$-0.66$-0.69$-0.66$-0.60$-0.58$-0.58$-0.96$-0.87$-0.60$-0.49$-0.62$-0.80$-0.71$-0.71$-0.57$-0.41$-0.98$-0.90$-0.97$-0.84$-1.25$-0.76$-1.70$-1.99$-2.48$-2.88$-3.78$-4.44$-5.59
Low Forecast$-1.36$-1.66$-1.73$-1.68$-1.53$-1.46$-1.47$-1.02$-1.16$-1.52$-1.25$-1.56$-1.26$-1.79$-1.81$-1.45$-1.04$-0.98$-0.90$-0.97$-0.84$-1.25$-0.76$-1.70$-1.99$-2.48$-2.88$-3.78$-4.44$-5.59
Surprise %-------------0.88%0.00%1.59%1.44%0.84%1.18%1.01%3.10%1.00%3.85%13.60%0.75%0.73%0.94%1.23%1.22%0.78%

According to undefined Wall Street analysts, Viridian Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to VRDN previous annual EPS of $NaN (undefined).

Viridian Therapeutics Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
INZYInozyme Pharma$2.94$16.00444.22%Buy
GPCRStructure Therapeutics$31.48$99.00214.49%Buy
TERNTerns Pharmaceuticals$6.80$18.67174.56%Buy
PLRXPliant Therapeutics$14.37$35.50147.04%Buy
KURAKura Oncology$9.74$23.33139.53%Buy
SNDXSyndax Pharmaceuticals$13.63$31.67132.36%Buy
CYTKCytokinetics$47.78$90.0088.36%Buy
MRUSMerus$44.90$81.2580.96%Buy
PCVXVaxcyte$89.86$148.8065.59%Buy
REPLReplimune Group$11.72$19.0062.12%Buy
ETNB89bio$7.98$12.0050.38%Buy
RVMDRevolution Medicines$45.16$65.6745.42%Buy
PTGXProtagonist Therapeutics$40.69$57.3340.89%Buy
ACLXArcellx$82.03$111.6036.05%Buy
NUVLNuvalent$88.10$114.8030.31%Buy
BPMCBlueprint Medicines$96.48$122.6027.07%Buy
CRNXCrinetics Pharmaceuticals$55.37$69.0024.62%Buy
VRDNViridian Therapeutics$20.82$22.759.27%Buy

VRDN Forecast FAQ

Is Viridian Therapeutics a good buy?

Yes, according to 11 Wall Street analysts, Viridian Therapeutics (VRDN) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 10 'Buy' recommendations, accounting for 90.91% of VRDN's total ratings.

What is VRDN's price target?

Viridian Therapeutics (VRDN) average price target is $22.75 with a range of $19 to $28, implying a 19.55% from its last price of $19.03. The data is based on 11 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Viridian Therapeutics stock go up soon?

According to Wall Street analysts' prediction for VRDN stock, the company can go up by 19.55% (from the last price of $19.03 to the average price target of $22.75), up by 47.14% based on the highest stock price target, and down by -0.16% based on the lowest stock price target.

Can Viridian Therapeutics stock reach $30?

VRDN's average twelve months analyst stock price target of $22.75 does not support the claim that Viridian Therapeutics can reach $30 in the near future.

What are Viridian Therapeutics's analysts' financial forecasts?

Viridian Therapeutics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $277.5K (high $370K, low $185K), average EBITDA is $-278K (high $-185K, low $-370K), average net income is $-273M (high $-180M, low $-364M), average SG&A $19.22M (high $25.63M, low $12.81M), and average EPS is $-4.104 (high $-2.717, low $-5.481). VRDN's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $25.97M (high $34.62M, low $17.31M), average EBITDA is $-25.968M (high $-17.312M, low $-34.624M), average net income is $-298M (high $-169M, low $-427M), average SG&A $1.8B (high $2.4B, low $1.2B), and average EPS is $-4.49 (high $-2.544, low $-6.436).

Did the VRDN's actual financial results beat the analysts' financial forecasts?

Based on Viridian Therapeutics's last annual report (Dec 2023), the company's revenue was $314K, which missed the average analysts forecast of $670.21K by -53.15%. Apple's EBITDA was $-254M, beating the average prediction of $-670K by 37865.71%. The company's net income was $-238M, missing the average estimation of $-299M by -20.36%. Apple's SG&A was $95M, beating the average forecast of $46.43M by 104.63%. Lastly, the company's EPS was $-0.0053, missing the average prediction of $-4.494 by -99.88%. In terms of the last quarterly report (Sep 2023), Viridian Therapeutics's revenue was $72K, missing the average analysts' forecast of $145.25K by -50.43%. The company's EBITDA was $-51.224M, beating the average prediction of $-145K by 35166.09%. Viridian Therapeutics's net income was $-47.66M, missing the average estimation of $-82.72M by -42.38%. The company's SG&A was $20.91M, beating the average forecast of $10.06M by 107.83%. Lastly, the company's EPS was $-1.09, missing the average prediction of $-1.245 by -12.48%